TREA

79355609 - SOM BIOTECH

Follow

Information

  • Trademark
  • 79355609
  • Serial Number
    79355609
  • Registration Number
    7404026
  • Filing Date
    July 20, 2022
    2 years ago
  • Registration Date
    June 04, 2024
    11 months ago
  • Transaction Date
    December 07, 2024
    5 months ago
  • Status Date
    June 04, 2024
    11 months ago
  • Published for Opposition Date
    March 19, 2024
    a year ago
  • Location Date
    June 03, 2024
    11 months ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    HARMON, RAYMOND
  • Attorney Docket Number
    TM11248US00
    Attorney Name
    Justin R. Young
  • Owners
Information
Mark Drawing Code
5
Mark Identification
SOM BIOTECH
Case File Statements
  • DM0000: The mark consists of the words "SOM BIOTECH" written in capital stylized letters. The word "SOM" is depicted in red, grey and black and it is represented in bigger letters than the word "BIOTECH", which is located under "SOM" and it is represented in grey in a smaller size.
  • GS0051: Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous system, metabolic disorders, malignant tumors, for activating cellular function, for cardiovascular and cerebrovascular diseases, for the treatment of Parkinson's disease, for the prevention of diseases of the respiratory system, for gastro-intestinal disorders, for the treatment of infectious diseases, for movement disorders, for oncologic diseases, for immune system diseases, for skeletal muscular diseases, for hormone disorders, for skin diseases, for ophthalmologic disease, for gynecological diseases, for hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington disease, Tourette disease, tardive dyskinesia, hereditary muscular dystrophies, hereditary metabolic disorders, hereditary neurological diseases, amyloidosis, rare neurodegenerative diseases, myotonic dystrophy, spinal muscular atrophy, idiopathic pulmonary fibrosis, multiple sclerosis, neurofibromatosis, Acute Flaccid Myelitis, Devic's syndrome, rare cancers, neuropathic pain, ELA and diabetes; pharmaceuticals, for use in the field of treatment of hereditary diseases being Huntington's Disease, Phenylketonuria, Tay Sachs, Duchenne Muscular Dystrophy, Dystrophinopathies, GM2 gangliosidoses, Niemann Pick Disease, hereditary amyloidosis, hereditary Parkinson's Disease, adrenoleukodystrophy, Dravet syndrome, Batten disease, Fragile X syndrome, Friedrich Ataxia, Lennox Gastaut, Gaucher disease, cystic fibrosis, acute myeloid leukemia, sickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals, for use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticals, for use in the treatment of skeletal muscular diseases; pharmaceuticals, for use in the treatment of hormone disorders; pharmaceuticals, for use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticals, for use in the treatment of gynaecological diseases; pharmaceuticals, for use in the treatment of haematological diseases; pharmaceuticals, for use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumors, namely, tumor antigens; biopharmaceuticals for the treatment of cancer
  • CC0000: The color(s) black, grey and red is/are claimed as a feature of the mark.
  • DS0000: "BIOTECH"
  • GS0421: Clinical research in the field of development of drugs discovered through artificial intelligence technology; biological research; chemical technological research in the field of development of drugs discovered through artificial intelligence technology; biomedical research services; research services in the fields of computation chemistry; medical and pharmacological research services in the field of drug discovery and development through artificial intelligence technology; research and development of vaccines and medicines; research and development in the field of microorganisms and cells; stem cell research services; research in the field of artificial intelligence technology; development of pharmaceutical preparations and medicines; implementation of preclinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; clinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; providing scientific information about the results of clinical trials for pharmaceutical products; consultancy pertaining to pharmacology; consultancy relating to research in the field of pharmacogenetics; consultancy relating to pharmaceutical research and development; chemistry consultation; providing information on the subject of scientific research in the field of biochemistry and biotechnology; laboratory analysis in the field of chemistry; design and development of medical technology; information technology (IT) consulting services for the pharmaceutical and healthcare industries; design and development of computer software for use with medical technology; design and development in relation to artificial intelligence technology; drug repositioning research; drug combination research
Case File Event Statements
  • 11/17/2022 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 11/25/2022 - 2 years ago
    2 - LIMITATION FROM ORIGINAL APPLICATION ENTERED Type: LIMI
  • 11/28/2022 - 2 years ago
    3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 12/2/2022 - 2 years ago
    4 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 5/5/2023 - 2 years ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/16/2023 - 2 years ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/17/2023 - 2 years ago
    7 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 6/26/2023 - a year ago
    8 - NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW Type: RFWR
  • 6/29/2023 - a year ago
    9 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/30/2023 - a year ago
    10 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 8/5/2023 - a year ago
    11 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 8/5/2023 - a year ago
    12 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 8/28/2023 - a year ago
    13 - REFUSAL PROCESSED BY IB Type: RFNT
  • 1/10/2024 - a year ago
    14 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 1/10/2024 - a year ago
    15 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 1/10/2024 - a year ago
    16 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 1/10/2024 - a year ago
    17 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 1/10/2024 - a year ago
    18 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 1/10/2024 - a year ago
    19 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 2/1/2024 - a year ago
    20 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/1/2024 - a year ago
    21 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/2/2024 - a year ago
    22 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/14/2024 - a year ago
    23 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 2/14/2024 - a year ago
    24 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 2/14/2024 - a year ago
    25 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 2/14/2024 - a year ago
    26 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 2/14/2024 - a year ago
    27 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/14/2024 - a year ago
    28 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 2/14/2024 - a year ago
    29 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 2/14/2024 - a year ago
    30 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 2/28/2024 - a year ago
    31 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/28/2024 - a year ago
    32 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 3/19/2024 - a year ago
    34 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/19/2024 - a year ago
    33 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/17/2024 - a year ago
    36 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 4/17/2024 - a year ago
    35 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 5/7/2024 - a year ago
    37 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 6/4/2024 - 11 months ago
    38 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 6/4/2024 - 11 months ago
    39 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 9/4/2024 - 8 months ago
    40 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 11/15/2024 - 6 months ago
    41 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 11/16/2024 - 6 months ago
    42 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 12/7/2024 - 5 months ago
    43 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO